The Unified Patent Court refused to grant a second preliminary injunction for 10x Genomics against rival biotech company NanoString in Munich today, October 10.
Presiding judge Matthias Zigann said the panel was unconvinced that NanoString had infringed 10x’s patent.
The judge said the panel’s findings on infringement and validity were not prejudicial on the main proceedings.
10x won the first full PI hearing in the court’s history last month over a separate but related patent. That ruling meant NanoString cannot sell its allegedly infringing products in 17 European countries while proceedings are ongoing.
The lawsuit concerns NanoString’s CosMx Spatial Molecular Imager device and CosMx reagents for RNA detection.
10x claimed NanoString infringed patents related to Xenium, the company’s own RNA analysis tool that it launched in December 2022.
There is parallel litigation between the parties at the US District Court for the District of Delaware, where 10x has also filed two infringement lawsuits.
Trials have been scheduled in Delaware in November 2023 and September 2024.
NanoString has argued that 10x’s technology was originally developed at Harvard University with grant funding from the US National Institutes of Health, with the intention it would be made widely available via licensing.
Harvard exclusively licensed the technology to ReadCoor, which was acquired by 10x in 2020.
“In contrast with the promises made in the grant application, 10x is now using the acquired ReadCoor patents in lawsuits designed to reduce the scientific community’s access to innovative technologies intended for broad access,” NanoString has claimed.
Germany’s Federal Patent Court has also issued a preliminary opinion in which it found the claims of one of 10x’s key patents to be valid. An oral hearing has been scheduled for May 2024.
The Munich Regional Court, meanwhile, granted an injunction in favour of 10x in May this year. NanoString has appealed against that ruling to the Higher Regional Court.
10x may yet appeal the latest UPC ruling. The UPC has yet to schedule a date for a trial on the merits of the case.
